Four routes for leukemic transformation guided by TP53 have been recently described using TARGET-seq: (1) acquisition of biallelic TP53 mutations, (2) acquisition of one TP53 variant followed by deletion of WT allele, (3) concomitant evolution of 2 subclones with different TP53 mutations, and (4) expansion of a clone harboring TP53 biallelic mutation while being negative for an MPN driver in a JAK2V617F-positive patient [92]. This evidence concerns the gene TP53 and myeloproliferative disorder.